Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc 簡介



公司代碼ALKS

公司名稱Alkermes Plc

上市日期Jul 16, 1991

CEOPops (Richard F)

員工數量1800

證券類型Ordinary Share

年結日Jul 16

公司地址Connaught House

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編D04 C5Y6

電話35317728000

網址https://www.alkermes.com/

公司代碼ALKS

上市日期Jul 16, 1991

CEOPops (Richard F)

Alkermes Plc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.39K

-6.12%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.39K

-6.12%

Mr. Brian P. McKeon

Independent Director

48.54K

+9.62%

Mr. Brian P. McKeon

Independent Director

48.54K

+9.62%

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. Richard F. Pops

Non-Executive Chairman of the Board

1.38M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

223.42K

-0.91%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

Mr. Shane M. Cooke

Independent Director

106.68K

+2.75%

常見問題

Alkermes Plc的前五大股東是誰？



Alkermes Plc的前五大股東如下：Mr. Richard F. Pops

有多少機構持有Alkermes Plc(ALKS)的股份？



截至2026Q1，共有783家機構持有Alkermes Plc的股份，合計持有的股份價值約為182.39M，占公司總股份的109.43% 。與2025Q4相比，機構持股有所增加，增幅為-11997400.00。

哪個業務部門對Alkermes Plc的收入貢獻最大？



在2026Q1，VIVITROL業務部門對Alkermes Plc的收入貢獻最大，創收124.45M，占總收入的25.09% 。